A practical reference on research compound: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
A variety of agents are added to sequester (deactivate) metal ions that otherwise catalyze the oxidation of fats. Common sequestering agents are disodium EDTA, citric acid (and citrates), tartaric acid, and lecithin.
Bhutan: Starting primarily in the 1990s, the Bhutanese government implemented strict restrictions on the country's ethnically Nepali Lhotshampa population and implemented internal border control policies to restrict immigration or return of ethnic Nepalis, creating a refugee crisis. This policy shift effectively ended previously liberal immigration policies concerning Nepalis and counts among the most racialised border control policies in Asia. China: China does not currently recognise North Korean defectors as refugees and subjects them to immediate deportation if caught. The China-DPRK border is fortified, and both sides aim to deter refugees from crossing. Human rights organisations have criticised this aspect of Chinese border control policy. Cyprus: As a result of Northern Cyprus's sovereignty dispute with Southern Cyprus, the South (a member of the European Union) has imposed restrictions on the North's airports, and pressure from the European Union has resulted in all countries other than Turkey recognising the South's ability to impose a border shutdown on the North, thus negating the right to self determination of the predominantly Turkish Northern Cypriot population and subjecting their airports to border controls imposed by the predominantly Greek South. As a result, Northern Cyprus is heavily dependent on Turkey for economic support and is unable to develop a functioning economy. Israel: Border control, both on entry and on exit, at Israeli airports rates passengers' potential threat to security using factors including nationality, ethnicity, and race.
Indoor combustion, such as for cooking or heating, is a major cause of indoor air pollution and causes significant health harms and premature deaths. Hydrocarbon fires cause air pollution. Pollution is caused by both biomass and fossil fuels of various types, but some forms of fuels are more harmful than others. Indoor fire can produce black carbon particles, nitrogen oxides, sulfur oxides, and mercury compounds, among other emissions. Around 3 billion people cook over open fires or on rudimentary cook stoves. Cooking fuels are coal, wood, animal dung, and crop residues. IAQ is a particular concern in low and middle-income countries where such practices are common. Cooking using natural gas (also called fossil gas, methane gas or simply gas) is associated with poorer indoor air quality. Combustion of gas produces nitrogen dioxide and carbon monoxide, and can lead to increased concentrations of nitrogen dioxide throughout the home environment which is linked to respiratory issues and diseases.
Sources: en.wikipedia.org
== Conjugated zwitterions == Strongly polarized conjugated compounds (conjugated zwitterions) are typically very reactive, share diradical character, activate strong bonds and small molecules, and serve as transient intermediates in catalysis. Donor-acceptor entities are of vast use in photochemistry (photoinduced electron transfer), organic electronics, switching and sensing.
Ceremonial San Pedro use seems to be characterized by relatively strong spiritual experiences, and low incidence of challenging experiences. DMT (N,N-dimethyltryptamine) is an indole alkaloid found in various species of plants. Traditionally, it is consumed by tribes in South America in the form of ayahuasca. A brew is used that consists of DMT-containing plants as well as plants containing monoamine oxidase inhibitors (MAOIs), like harmine and harmaline, which allows DMT to be consumed orally without being rendered inactive by monoamine oxidase (MAO) enzymes in the digestive system. A pharmaceutical version of ayahuasca is called pharmahuasca. In the Western world, DMT is more commonly consumed via the vaporisation of freebase DMT. Whereas ayahuasca typically lasts for several hours, inhalation has an onset measured in seconds and has effects measured in minutes, being much more intense. Particularly in smoked or vaporised form, DMT has the ability to cause users to enter a hallucinatory realm fully detached from reality, being typically characterised by hyperbolic geometry, and described as defying visual or verbal description. Users have also reported encountering and communicating with entities within this hallucinatory state. DMT is the archetypal substituted tryptamine, being the structural scaffold of psilocybin and, to a lesser extent, the lysergamides. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine; mebufotenin) is a naturally occurring substituted 5-methoxytryptamine which was first identified as having psychedelic effects in the 1960s.
Cooper's decision to name his capsule Faith 7 was based on the faith he had in the Atlas booster and Mercury capsule to carry out the mission successfully, although it was reported in The Washington Post that some NASA officials were skeptical of the idea.
Those whose half-lives exceed a few percent of the age of the Earth (about 4.6×109 years) survive from its formation and are remnants of nucleosynthesis that occurred in stars before the formation of the Solar System. For example, the isotope 23892U (t1/2 = 4.463×109 years) of uranium is still fairly abundant in nature, but the shorter-lived isotope 23592U (t1/2 = 0.704×109 years) is now 138 times rarer. 35 of these primordial radionuclides have been identified (see List of nuclides and Primordial nuclide for details). Radiogenic nuclides (such as 22688Ra (t1/2 = 1600 years), an isotope of radium) that are formed by radioactive decay. They occur in the decay chains of primordial isotopes of uranium or thorium. Some of these nuclides are very short-lived, such as isotopes of francium. There exist about 50 of these daughter nuclides that have half-lives too short to be primordial, and which exist in nature solely due to decay from longer lived radioactive primordial nuclides. Nuclides that are continuously being made in another fashion that is not simple spontaneous radioactive decay (i.e., only one atom involved with no incoming particle) but instead involves a natural nuclear reaction. These occur when atoms react with natural neutrons (from cosmic rays, spontaneous fission, or other sources), or are bombarded directly with cosmic rays. The latter, if non-primordial, are called cosmogenic nuclides. Other types of natural nuclear reactions produce nuclides that are said to be nucleogenic nuclides.
Sources: en.wikipedia.org
•NO + O3 → •NO2 + O2 + hν The activated NO2[◊] luminesces broadband visible to infrared light as it reverts to a lower energy state. A photomultiplier and associated electronics count the photons that are proportional to the amount of nitric oxide (NO) present. To determine the amount of nitrogen dioxide, NO2, in a sample (containing no NO), it must first be converted to NO by passing the sample through a converter before the above ozone activation reaction is applied. The ozone reaction produces a photon count proportional to NO that is proportional to NO2 before it was converted to NO. In the case of a mixed sample that contains both NO and NO2, the above reaction yields the amount of NO and NO2 combined in the air sample, assuming that the sample is passed through the converter. If the mixed sample is not passed through the converter, the ozone reaction produces activated NO2[◊] only in proportion to the NO in the sample. The NO2 in the sample is not activated by the ozone reaction. Though unactivated NO2 is present with the activated NO2[◊], photons are emitted only by the activated species that is proportional to original NO. The final step is to subtract NO from (NO + NO2) to yield NO2
=== Early study === The history of oligopeptidases originates in the late 1960s, when the rabbit brain was searched for enzymes that cause inactivation of the nonapeptide bradykinin. In the early and mid 1970s two thiol-activated endopeptidases, responsible for more than 90% of bradykinin inactivation, were isolated from cytosol of rabbit brain, and characterized. They correspond to EOPA (endooligopeptidase A, EC 3.4.22.19), and Prolyl endopeptidase or Prolyl oligopeptidase (POP) (EC 3.4.21.26). Since their activities are restricted to oligopeptides (usually from 8-13 amino acid residues), and do not hydrolyze proteins or large peptides (>30 amino acid residues), they were designated oligopeptidases. In the early and mid 1980s other oligopeptidases, mostly metallopeptidases, were described in the cytosol of mammalian tissues, such as the TOP (thimet oligopeptidase, EC 3.4.24.15), and the neurolysin (EC 3.4.24.16). Earlier on, the ACE (angiotensin-converting enzyme, EC 3.4.15.1), and the NEP (neprilysin, EC 3.4.24.11), had been described, at the end of the 1960s, and in 1973, respectively.
For transition metals, common oxidation states are nearly always at least +2 for similar reasons (uncovering the next subshell); this holds even for the metals with anomalous dx+1s1 or dx+2s0 configurations (except for silver), because repulsion between d-electrons means that the movement of the second electron from the s- to the d-subshell does not appreciably change its ionisation energy. Because ionizing the transition metals further does not uncover any new inner subshells, their oxidation states tend to vary by steps of 1 instead. The lanthanides and late actinides generally show a stable +3 oxidation state, removing the outer s-electrons and then (usually) one electron from the (n−2)f orbitals, that are similar in energy to ns. The common and maximum oxidation states of the d- and f-block elements tend to depend on the ionisation energies. As the energy difference between the (n−1)d and ns orbitals rises along each transition series, it becomes less energetically favourable to ionize further electrons. Thus, the early transition metal groups tend to prefer higher oxidation states, but the +2 oxidation state becomes more stable for the late transition metal groups. The highest formal oxidation state thus increases from +3 at the beginning of each d-block row, to +7 or +8 in the middle (e.g. OsO4), and then decrease to +2 at the end.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.